{"id":"NCT00623428","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response","officialTitle":"A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2008-02-26","resultsPosted":"2013-06-24","lastUpdate":"2013-07-22"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"peginterferon alfa-2a","otherNames":["Pegasys®","PEG-IFN alfa-2a"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus®"]}],"arms":[{"label":"PEG-IFN alfa-2a + Ribavirin for 24 weeks","type":"EXPERIMENTAL"},{"label":"PEG-IFN alfa-2a + Ribavirin for 48 weeks","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.","primaryOutcome":{"measure":"Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment","timeFrame":"24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.","effectByArm":[{"arm":"PEG-IFN Alfa-2a + Ribavirin for 24 Weeks","deltaMin":52,"sd":null},{"arm":"PEG-IFN Alfa-2a + Ribavirin for 48 Weeks","deltaMin":57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4557"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":101,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Germany","Mexico","Puerto Rico","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":95},"commonTop":["Fatigue","Headache","Insomnia","Pruritus","Nausea"]}}